Mondobiotech

Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.

Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.

Short Reads

Premium

Broad Institute, Expression Analysis, Helicos BioSciences, University of Texas at Austin, Applied Biosystems, University of Georgia, ABRF, Genomatix, Illumina, Mondobiotech, 23andMe, Kapa Biosystems

BioArray Briefs

Premium

Cancer Research UK, Fluidigm, Fox Chase Cancer Center, BioDiscovery, Mondobiotech, 23andMe

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.